PANDION THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pandion Therapeutics, Inc. - PAND

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pandion Therapeutics, Inc. (NasdaqGS: PAND) to Merck (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Pandion will receive only $60.00 in cash for each share of Pandion that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or